YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Bristol Myers BMY is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line growth amid a significant decline in legacy drug sales. These key drugs are part of the company's growth portfolio, w…
Keros Therapeutics KROS announced that it has dosed the first patient in the phase II study evaluating its lead pipeline candidate, rinvatercept, in patients with Duchenne muscular dystrophy (DMD). The open-label, multi-cohort basket study…
A month has gone by since the last earnings report for Keros Therapeutics, Inc. (KROS). Shares have added about 8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue l…
Keros Therapeutics KROS is set to receive a $20 million development milestone from Takeda after the first patient was dosed in the phase III ELRiSE study of elritercept. The payment adds near-term financial flexibility while advancing a pa…
Keros Therapeutics KROS reported a second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. Revenues fell to zero from $18.2 million a year earlier. The investment case now rests heavily on r…
On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 E…
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseas…
Keros Therapeutics KROS reported second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share reported in the year-ago quarter. Keros recorde…
Keros Therapeutics, Inc. LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to trea…
Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items. This quar…
Nurix Therapeutics, Inc. (NRIX) shares soared 16.4% in the last trading session to close at $22.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.5% gain o…
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, announced on Thursday the appointment of Anne Prener to its Board of Directors, effective from July 1, 2026. Prener currently serves as a Senior Innov…
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patient…
Keros Therapeutics KROS is recasting itself as a neuromuscular execution story, anchored by rinvatercept (KER-065) and a catalyst path that begins in 2026. The shift comes as the company leans into selective transforming growth factor-β (T…
Keros Therapeutics KROS posted a messy first-quarter 2026 print, with a wider-than-expected loss and a steep revenue decline. The headline numbers look worse than the underlying operating reality because Keros is still pre-commercial and i…
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing protein therapeutics that modulate transforming growth factor-beta family signaling across skeletal muscle, bone, and adipose tissue, among other areas. Headi…
Keros Therapeutics KROS incurred first-quarter 2026 loss of $1.21 per share, wider than the Zacks Consensus Estimate of a loss of 92 cents. The company had recorded earnings of $3.62 per share in the year-ago quarter. KROS does not have an…
Keros Therapeutics KROS enters 2026 with a tighter focus on rinvatercept and a reshaped cost profile after moving elritercept development spending to Takeda. The next 12 months are set up as an execution story, with timelines and partner a…
Keros Therapeutics KROS is tightening its focus around rinvatercept, a protein therapeutic designed to modulate transforming growth factor-beta family ligands tied to skeletal muscle, bone, and adipose biology. That narrower strategy puts…
A month has gone by since the last earnings report for Keros Therapeutics, Inc. (KROS). Shares have added about 2.5% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue…
Insmed INSM shares rallied 5.5% in the last trading session to close at $153.32. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.7% loss…
Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program around a clear biology-driven thesis: impro…
Keros Therapeutics KROS enters 2026 with a clearer catalyst stack and a tighter operational focus. The near-term setup is led by rinvatercept, with study starts and regulatory interactions now mapped in a way that turns planning into execu…
Keros Therapeutics KROS posted a dramatic revenue jump in 2025, but the mix matters as much as the magnitude. The shares also trade at a steep discount to book value, creating the classic biotech question: deep value setup or value trap. T…
Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of…
Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line growth amid a significant decline in legac…
We expect investors to focus on pipeline updates when Keros Therapeutics KROS reports fourth-quarter results shortly. The Zacks Consensus Estimate for sales and loss per share is pegged at $6.50 million and 49 cents, respectively. Earnings…
Bristol Myers’ BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line growth in the upcoming quarterly results.…
Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) aged 4 to 7 years at the time of dosing.…
Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of…
Clinical-stage biopharma company Janux Therapeutics JANX announced a strategic collaboration and exclusive global license agreement with biotech giant Bristol Myers Squibb BMY. The partnership centers on Janux’s proprietary Tumor Activated…
Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 1…
Marker Therapeutics’ MRKR shares have surged approximately 114% over the past three months, driven by strong momentum surrounding its early-stage lead candidate, MT-601, which has boosted investor confidence. Marker, a Texas-based cancer b…
Novartis NVS announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the treatment of adult patients with Sjogren’s disease — a chronic, systemic autoimmune disorder. Ianalumab is an investi…
Novartis NVS announced that the FDA granted Breakthrough Therapy designation to its pipeline candidate, ianalumab for the treatment of adult patients with Sjogren’s disease — a chronic, systemic autoimmune disorder. Ianalumab is an investi…
Axsome Therapeutics AXSM announced the initiation of the phase III study called FORWARD with the dosing of the first patient, evaluating AXS-14 (esreboxetine) for the management of fibromyalgia. AXS-14 is an oral, investigational drug, bei…